Company: ACBM
Filing Date: 2025-07-18
Form Type: 10-K
Source: 0001640334-25-001245
Chunk: 39

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-18
Form: 10-K
Item: Item 1
Chunk 39
---
  60,042   60,042 Additional paid-in capital  32,298,442   32,295,236 Deferred stock compensation  -   (8,060,983)Accumulated deficit  (32,615,498)  (23,807,925)Total Stockholders’ (Deficit) Equity   (257,014)  486,370          TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) $58,459  $687,486 

The accompanying notes are an integral part of these financial statements.

 F-4Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Operations

  Year Ended   December 31,   2023  2022        Revenues $-  $658,500 Cost of revenues  -   518,000 Gross profit  -   140,500          Operating expenses        Selling, general and administrative   3,517,542   5,930,237 Research and development  4,794,825   10,080,000 Provision for doubtful accounts  480,000   - Provision for purchase deposit write-off  12,000   -    Total operating expenses  8,804,367   16,010,237          Loss from operations  (8,804,367)  (15,869,737)         Other expense        Interest expense - related parties  3,206   1,706    Total other expenses  3,206   1,706          Loss before income tax expense  (8,807,573)  (15,871,443)Income tax expense   -   - Net loss $(8,807,573) $(15,871,443)         Basic and diluted loss per share of common stock $(0.15) $(0.26)         Weighted average number of shares of common stock outstanding  60,042,000   60,042,000 

The accompanying notes are an integral part of these financial statements.

 F-5Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Changes in Stockholders’ Equity (Deficit)